Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients.

摘要: Background Tigecycline was approved for the treatment of complicated intra-abdominal and skin/skin structure infections. Because its in vitro effectiveness multidrug-resistant (MDR) isolates, tigecycline has been prescribed more broadly. This study evaluated use after first introduction Taiwan experience with the treatment MDR Acinetobacter baumannii (MDRAB) infection, especially ventilator-associated pneumonia. Methods Patients treated were collected retrospectively from February 2008 to July Taipei Veterans General Hospital, a 2,900-bed tertiary care medical center Taiwan. divided into three groups according indications: Group 1, Food Drug Administration–approved indications; 2, health care–associated pneumonia (HAP); 3, urinary tract osteomyelitis, bacteremia, etc. Cases MDRAB also identified. Results Among 66 cases, indications administration included (12, 18.2%), HAP (38, 57.6%), bacteremia (3, 4.5%), catheter-related infections infection (4, 6.1%), osteomyelitis (4, 6.1%), others (2, 3%). Clinical outcome positive 20 higher clinical success rate 1 than which may correlate Sequential Organ Failure Assessment score, older age, frequent intensive admission 2. Of microbiologically evaluable predominated (33/51, 64.7%). (excluding without ventilator), 12% (3/25). Conclusions The most common indication prescription HAP. Success lower that previously reported, possibly because serious underlying conditions comorbidities our patients. limited choices, physicians should weigh risk benefit prescribing tigecycline.